Cargando…
Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (Lacticaseibac...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914668/ https://www.ncbi.nlm.nih.gov/pubmed/33567701 http://dx.doi.org/10.3390/nu13020558 |
_version_ | 1783657057253064704 |
---|---|
author | Kanazawa, Akio Aida, Masanori Yoshida, Yasuto Kaga, Hideyoshi Katahira, Takehiro Suzuki, Luka Tamaki, Shoko Sato, Junko Goto, Hiromasa Azuma, Kosuke Shimizu, Tomoaki Takahashi, Takuya Yamashiro, Yuichiro Watada, Hirotaka |
author_facet | Kanazawa, Akio Aida, Masanori Yoshida, Yasuto Kaga, Hideyoshi Katahira, Takehiro Suzuki, Luka Tamaki, Shoko Sato, Junko Goto, Hiromasa Azuma, Kosuke Shimizu, Tomoaki Takahashi, Takuya Yamashiro, Yuichiro Watada, Hirotaka |
author_sort | Kanazawa, Akio |
collection | PubMed |
description | The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (Lacticaseibacillus paracasei strain Shirota (previously Lactobacillus casei strain Shirota) and Bifidobacterium breve strain Yakult, and galactooligosaccharides). The primary endpoint was the change in interleukin-6 from baseline to 24 weeks. Secondary endpoints were evaluation of the gut microbiota in feces and blood, fecal organic acids, high-sensitivity C-reactive protein, lipopolysaccharide-binding protein, and glycemic control. Synbiotic administration for 24 weeks did not significantly affect changes in interleukin-6 from baseline to 24 weeks (0.35 ± 1.99 vs. −0.24 ± 1.75 pg/mL, respectively). Relative to baseline, however, at 24 weeks after synbiotic administration there were positive changes in the counts of Bifidobacterium and total lactobacilli, the relative abundances of Bifidobacterium species such as Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum, and the concentrations of acetic and butyric acids in feces. No significant changes in inflammatory markers were found in the synbiotic group compared to the control group. However, synbiotic administration at least partially improved the gut environment in obese patients with type 2 diabetes. |
format | Online Article Text |
id | pubmed-7914668 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79146682021-03-01 Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study Kanazawa, Akio Aida, Masanori Yoshida, Yasuto Kaga, Hideyoshi Katahira, Takehiro Suzuki, Luka Tamaki, Shoko Sato, Junko Goto, Hiromasa Azuma, Kosuke Shimizu, Tomoaki Takahashi, Takuya Yamashiro, Yuichiro Watada, Hirotaka Nutrients Article The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (Lacticaseibacillus paracasei strain Shirota (previously Lactobacillus casei strain Shirota) and Bifidobacterium breve strain Yakult, and galactooligosaccharides). The primary endpoint was the change in interleukin-6 from baseline to 24 weeks. Secondary endpoints were evaluation of the gut microbiota in feces and blood, fecal organic acids, high-sensitivity C-reactive protein, lipopolysaccharide-binding protein, and glycemic control. Synbiotic administration for 24 weeks did not significantly affect changes in interleukin-6 from baseline to 24 weeks (0.35 ± 1.99 vs. −0.24 ± 1.75 pg/mL, respectively). Relative to baseline, however, at 24 weeks after synbiotic administration there were positive changes in the counts of Bifidobacterium and total lactobacilli, the relative abundances of Bifidobacterium species such as Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum, and the concentrations of acetic and butyric acids in feces. No significant changes in inflammatory markers were found in the synbiotic group compared to the control group. However, synbiotic administration at least partially improved the gut environment in obese patients with type 2 diabetes. MDPI 2021-02-08 /pmc/articles/PMC7914668/ /pubmed/33567701 http://dx.doi.org/10.3390/nu13020558 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kanazawa, Akio Aida, Masanori Yoshida, Yasuto Kaga, Hideyoshi Katahira, Takehiro Suzuki, Luka Tamaki, Shoko Sato, Junko Goto, Hiromasa Azuma, Kosuke Shimizu, Tomoaki Takahashi, Takuya Yamashiro, Yuichiro Watada, Hirotaka Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
title | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
title_full | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
title_fullStr | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
title_full_unstemmed | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
title_short | Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study |
title_sort | effects of synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus: a randomized controlled study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914668/ https://www.ncbi.nlm.nih.gov/pubmed/33567701 http://dx.doi.org/10.3390/nu13020558 |
work_keys_str_mv | AT kanazawaakio effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT aidamasanori effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT yoshidayasuto effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT kagahideyoshi effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT katahiratakehiro effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT suzukiluka effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT tamakishoko effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT satojunko effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT gotohiromasa effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT azumakosuke effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT shimizutomoaki effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT takahashitakuya effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT yamashiroyuichiro effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy AT watadahirotaka effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy |